Search PubMed⌕ Search

PubMed · 12935664

Modelling postmortem surface cooling in continuously changing environmental temperature.

Abstract

Heat loss depends on the temperature gradient between body surface and environment. Skin cooling data in the forensic literature are scarce and models for skin cooling have not been developed. The dependence on the environmental temperature is a general problem in modelling postmortem cooling processes; most models of rectal cooling are therefore restricted to constant ambient temperatures. Since surface in contrast to core temperatures are highly sensitive to changes of ambient temperature, a model for skin cooling has to take into account such changes. The present study provides an estimator for the time-dependent function of the temperature decrease of the skin and presents a model of the cooling process. The formulae are developed on the basis of skin cooling data of the exposed skin of the forehead in a 40-year-old female (163 cm, 62.1 kg). The single exponential Newtonian model for the surface temperature T(S) valid for constant environmental temperature T(E):T(S)(t)=(T(S)(0)-T(E))e(-lambda(t))+T(E) is localized to small time intervals. By Taylor series expansions a differential equation directly providing an estimator for the temperature decrease rate lambda is derived. The solution of this differential equation represents the extended Newtonian model valid for non-constant environmental temperatures and non-constant temperature decrease rates. The extended model is tested successfully by reinserting the estimated values for the temperature decrease rate: the reconstructed and the measured skin temperature decrease curves completely overlap each other. The temperature decrease rate is a function of the difference between skin and environmental temperature and of the actual change of the skin temperature. A scatter plot of this function shows a structured cloud of points lying in one plane. The temperature decrease rate can thus be parametrized by a simple affine equation with three coefficients determined by linear regression. Inserting the affine equation in the extended Newtonian model leads to an inhomogeneous, non-linear differential equation which is solved by recursion. With knowledge of the initial temperature and the course of the environmental temperature the decrease of the skin temperature can be predicted with very good results. The model is validated with good results in 12 further experimental skin cooling curves of ten different individuals.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Gita Mall, Michael Hubig, Mona Eckl, Andreas Büttner, Wolfgang Eisenmenger. 2002. Modelling postmortem surface cooling in continuously changing environmental temperature.. https://doi.org/10.1016/s1344-6223(02)00013-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗